Roche confirms full-year 2016 outlook as Q1 sales beat forecast

Swiss drugmaker Roche reiterated on Tuesday that it expects to achieve its full-year targets after sales during the first three months of 2016 rose 4 percent, beating analyst expectations.

The Basel-based company expects sales to grow in the low- to mid-single-digit percentages at constant exchange rates, with faster growth of core earnings per share. It plans to boost its dividend in Swiss francs.

In a statement, Roche said first-quarter sales rose to 12.4 billion Swiss francs ($12.87 billion) compared to the 12.3 billion francs forecast by analysts in a Reuters poll.